secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001159036-25-000070
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170
--------------------------------------------------------------------------------

- Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.
- Shares vest based on achieving 20-trading-day average stock price of $115 (50%), $130 (100%), $145 (150%), or $170 (200%) over 4-year performance period.
- Time-based vesting requires continued employment through fourth anniversary; voluntary resignation/retirement forfeits all performance-vested shares.
- Grant intended to retain CEO and incentivize growth and profitability during next stage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/0001159036-25-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/halo-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer